Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
BridgeBio Pharma Inc (BridgeBio) is a biotechnology company that discovers, creates, tests, and delivers transformative medicines for genetic diseases. The company's main activities involve leveraging scientific advancements to develop breakthrough therapies for patients with unmet medical needs. Its products include investigational drugs such as attruby for transthyretin-mediated amyloidosis cardiomyopathy; and acoramidis for early-stage variant transthyretin amyloidosis. BridgeBio's pipeline products include Acoramidis for the prevention of early-stage variant transthyretin amyloidosis (ATTRv); Low-dose infigratinib for achondroplasia and hypochondroplasia; BBP-418; Encaleret for utosomal dominant hypocalcemia type 1; and BBP-812 for canavan disease. The company operates in the US, and Japan. BridgeBio is headquartered in Palo Alto, California, the US.
Headquarters
United States of America
Address
Suite 250, 3160 Porter Drive, Palo Alto, California, 94304
Website
bridgebio.com
Telephone
1 650 3919740
No of Employees
834
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
BBIO (NASD)
Revenue (2024)
$502.1M
126.3%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
-35.3%
(2024 vs 2023)
Market Cap*
$15.1B
Net Profit Margin (2024)
XYZ
40.2%
(2024 vs 2023)
* As of and is in US$
BridgeBio Pharma Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Pipeline | TRUSELTIQ |
| Attruby: Transthyretin-Mediated amyloidosis cardiomyopathy (ATTR-CM) | NULIBRY |
| Acoramidis: Early-Stage Variant Transthyretin amyloidosis (ATTRv) | |
| XYZ | |
| XYZ | |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | Regulatory Approval | In February, the company secured marketing authorization from the European Commission for acoramidis. |
| 2024 | Regulatory Approval | In November, the company received approval from the U.S. Food and Drug Administration for Attruby (acoramidis), an orally administered stabilizer of Transthyretin to treat adults with ATTR-CM to reduce cardiovascular death and cardiovascular-related hospitalization. |
| 2024 | Contracts/Agreements | In November, the company selected PANTHERx Rare to distribute Attruby (acoramidis). |
Competitor Comparison
| Key Parameters | BridgeBio Pharma Inc | Pfizer Inc | Sanofi | BioMarin Pharmaceutical Inc | Neurocrine Biosciences Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | France | United States of America | United States of America |
| City | Palo Alto | New York City | Paris | San Rafael | San Diego |
| State/Province | California | New York | Ile-de-France | California | California |
| No. of Employees | 834 | 75,000 | 76,493 | 3,221 | 2,000 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Neil Kumar, Ph.D. | Director; Chief Executive Officer | Executive Board | 2015 | 46 |
| Charles Homcy, M.D. | Chairman - Pharmaceuticals | Executive Board | 2024 | 76 |
| Eric Aguiar, M.D. | Director | Non Executive Board | 2024 | 63 |
| Fred Hassan | Director | Non Executive Board | 2021 | 70 |
| Jennifer E. Cook | Director | Non Executive Board | 2024 | 59 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer